Angelica Loskog – Immunostimulating gene and cell therapy for cancer
Our research focuses on developing cancer immunotherapy. We are inventing and evaluating novel therapies from preclinical research to clinical trials. We work in close contact with small biotech companies such as the Swedish based Lokon Pharma for product development.
The aim of cancer immunotherapy is to restart the immune cells to target and kill cancer cells by virtually the same mechanisms as used to kill virally infected cells. There are many approaches being tested in clinical trials around the world with promising effects. We have focused on CAR T cells and adenovirus-mediated immunostimulatory gene therapy.